Role of complex cyclin D1/Cdk4 in somatostatin subtype 2 receptor-mediated inhibition of cell proliferation of a medullary thyroid carcinoma cell line in vitro

Endocrinology

Volumn 147, Issue 7, 2006, Pages 3530-3538

  Tagliati, Federico ^a   Zatelli, Maria Chiara ^a   Bottoni, Arianna ^a   Piccin, Daniela ^a   Luchin, Andrea ^a   Culler, Michael D ^b   Degli Uberti, Ettore C ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b Biomeasure Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIM 23120; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; GLYCOGEN SYNTHASE KINASE 3BETA; HORMONE RECEPTOR BLOCKING AGENT; SOMATOSTATIN; SOMATOSTATIN RECEPTOR 2; UNCLASSIFIED DRUG;

ARTICLE; CARCINOMA CELL; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; ENZYME ACTIVITY; EVALUATION; HALF LIFE TIME; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; SEQUENCE HOMOLOGY; THYROID MEDULLARY CARCINOMA;

CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; DNA; G2 PHASE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; RECEPTORS, SOMATOSTATIN; RETINOBLASTOMA PROTEIN; SOMATOSTATIN; THYROID NEOPLASMS;

EID: 33745142615     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2005-1479     Document Type: Article

References (36)

1. Patel YC 1999 Somatostatin and its receptor family. Front Neuroendocrinol 20:157-198
2. Patel YC, Greenwood MT, Warszynska A, Panetta R, Srikant CB 1994 All five cloned human somatostatin receptors (hSST1-5) are functionally coupled to adenylyl cyclase. Biochem Biophys Res Commun 198:605-612
3. Vitale G, Tagliaferri P, Caraglia M, Rampone E, Ciccarelli A, Bianco AR, Abbruzzese A, Lupoli G 2000 Slow release lanreotide in combination with Interferon-α2b in the treatment of symptomatic advanced medullary thyroid carcinoma. J Clin Endocrinol Metab 85:983-988
4. Vitale G, Caraglia M, Ciccarelli A, Lupoli G, Abruzzese A, Tagliaferri P, Lupoli G 2001 Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer 91:1797-1808
5. Modigliani E, Cohen R, Joannidis S, Siame-Mourot C, Giuliana JM, Charpentier G, Cassuto D, Bentata Passayre M, Tabarin A, Roger P, Caron P, Guillausseau PJ, Lalau JD, Tourniaire J, Bayard F, Aufevre P, James-Deidier A, Calmettes C 1992 Results of long term continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma. Clin Endocrinol (Oxf) 36:183-186
6. Lupoli G, Cascone E, Arlotta F, Vitale G, Celentano L, Salvatore M, Lombardi G 1996 Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon α-2b and octreotide. Cancer 78:1114-1118
7. Zatelli MC, Tagliati F, Taylor JE, Rossi R, Culler MD, degli Uberti EC 2001 Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line TT. J Clin Endocrinol Metab 86:2161-2169
8. Zatelli MC, Tagliati F, Piccin D, Taylor JE, Culler MD, Bondanelli M, degli Uberti EC 2002 Somatostatin receptor subtype 1 selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line. Biochem Biophys Res Commun 297:821-827
9. Zatelli MC, Piccin D, Tagliati F, Bottoni A, Luchin A, degli Uberti EC 2005 SHP-1 restrains cell proliferation in medullary thyroid carcinoma. Endocrinology 146:2692-2698
10. Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J 1996 Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 271:20608-20616
11. degli Uberti EC, Hanau S, Rossi R, Piva R, Margutti A, Trasforini G, Pansini G, Del Senno L 1990 Somatostatin reduces 3H-thymidine incorporation and c-myc, but not thyroglobulin ribonucleic acid levels in human thyroid follicular cells in vitro. J Clin Endocrinol Metab 72:1364-1371
12. Rossi R, Zatelli MC, Franceschetti P, Maestri I, Magri E, Aguiari G, Cavazzini P, degli Uberti EC, del Senno L 1996 Inhibitory effect of dihydrotestosterone on human thyroid cell growth. J Endocrinol 151:185-194
13. Colamussi ML, Secchiero P, Gonelli A, Marchisio M, Zauli G, Capitani S 2001 Stromal derived factor-1α (SDF-1α) induces CD4+ T cell apoptosis via the functional up-regulation of the Fas (CD95)/Fas ligand (CD95L) pathway. J Leukoc Biol 69:263-270
14. Zatelli MC, Piccin D, Tagliati F, Ambrosio MR, Margutti A, Padovani R, Scanarini M, Culler MD, degli Uberti EC 2003 Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion. J Clin Endocrinol Metab 88:2797-2802
15. Keller C, Hyrien O, Knippers R, Krude T 2002 Site-specific and temporally controlled initiation of DNA replication in a human cell-free system. Nucleic Acids Res 30:2114-2123
16. Lahti JM, Li H, Kidd VJ 1997 Elimination of cyclin D1 in vertebrate cells leads to an altered cell cycle phenotype, which is rescued by overexpression of murine cyclins D1, D2, or D3 but not by a mutant cyclin D1. J Biol Chem 272:10859-10869
17. Diehl JA, Zindy F, Sherr CJ 1997 Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 11:957-972
18. Diehl JA, Cheng M, Roussel MF, Sherr CJ 1998 Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12:3499-3511
19. Alt JR, Cleveland JL, Hannink M, Diehl JA 2000 Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev 14:3102-3114
20. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA 1995 Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378:785-789
21. Choi YH, Lee SJ, Nguyen P, Jang JS, Lee J, Wu M-L, Takano E, Makii M, Henkart PA, Trepel JB 1997 Regulation of cyclin D1 by calpain protease. J Biol Chem 272:28479-28484
22. Bousquet C, Delesque N, Lopez F, Saint-Laurent N, Esteve JP, Bedecs K, Buscail L, Vaysse N, Susini C 1998 Sst2 somatostatin receptor mediates negative regulation of insulin receptor signaling through the tyrosine phosphatase SHP-1. J Biol Chem 273:7099-7106
23. Lopez F, Esteve JP, Buscail L, Delesque N, Saint-Laurent N, Theveniau M, Nahmias C, Vaysse N, Susini C 1997 The tyrosine phosphatase SHP-1 associates with the sst2 somatostatin receptor and is an essential component of sst2-mediated inhibitory growth signaling. J Biol Chem 272:24448-24454
24. Pages P, Benali N, Saint-Laurent N, Esteve JP, Schally AV, Tkaczuk J, Vaysse N, Susini C, Buscail L 1999 Sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP-1. J Biol Chem 274:15186-15193
25. Medina DL, Velasco JA, Santisteban P 1999 Somatostatin is expressed in FRTL-5 thyroid cells and prevents thyrotropin-mediated down-regulation of the Cyclin-dependent kinase inhibitor p27kip1. Endocrinology 140:87-95
26. Charland S, Boucher MJ, Houde M, Rivard N 2001 Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/p44 mitogen-activated protein (MAP) kinase activation in normal and tumoral pancreatic acinar cells. Endocrinology 142:121-128
27. Zatelli MC, Tagliati F, Taylor JE, Piccin D, Culler MD, degli Uberti EC 2002 Somatostatin, but not somatostatin receptor subtypes 2 and 5 selective agonists, inhibits calcitonin secretion and gene expression in the human medullary thyroid carcinoma cell line, TT. Horm Metab Res 34:229-233
28. Pagliacci MC, Tognellini R, Grignani F, Nicoletti I 1991 Inhibition of human breast cancer cell (MCF-7) growth in vitro by the somatostatin analog SMS 201-995: effects on cell cycle parameters and apoptotic cell death. Endocrinology 129:2555-2562
29. Whittaker SR, Walton MI, Garrett MD, Workman P 2004 The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Res 64:262-272
30. Teixeira C, Pratt MA 1997 CDK2 is a target for retinoic acid-mediated growth inhibition in MCF-7 human breast cancer cells. Mol Endocrinol 11:1191-1202
31. 2 phase delay. J Biol Chem 274:13961-13969
32. 1/S cyclin-dependent kinases. J Biol Chem 272:12738-12746
33. Malumbres M, Barbacid M 2001 To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1:222-231
34. Lundberg AS, Weinberg RA 1998 Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 18:753-761
35. Harbour JW, Dean DC 2000 The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 14:2393-2409
36. Lahlou H, Saint-Laurent N, Esteve JP, Eychene A, Pradayrol L, Pyronnet S, Susini C 2003 Sst2 somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation. J Biol Chem 278:39356-39371